美罗华
苯达莫司汀
医学
华登氏巨球蛋白血症
重症监护医学
化疗
伊布替尼
肿瘤科
内科学
淋巴瘤
慢性淋巴细胞白血病
白血病
作者
Christian Buske,M. Lia Palomba
标识
DOI:10.1016/j.hoc.2023.05.001
摘要
Despite substantial progress in the clinical management of Waldenström’s Macroglobulinemia (WM) and the emergence of chemotherapy-free approaches such as BTK inhibitors , WM is still a disease in which current treatments fail to cure and are in part associated with significant toxicities, compromising treatment outcome and quality of life . Thus, the vision for future front-line therapy should be to develop regimens which combine improved efficacy and excellent applicability with a low toxicity profile. Conventional immunochemotherapy such as bendamustine-rituximab is highly active but limited by hematotoxicity and long-lasting immunosuppression . Thus, further intensification of this treatment concept will most likely not be successful. Chemotherapy-free approaches such as BTK inhibitors have already changed the treatment landscape in WM, but still have major limitations such as the need for non-fixed duration treatment. Most probably, the combination of non-chemotherapy based, targeted approaches with different modes of action will ensure that we at least come closer to our vision of achieving functional cure in WM in the near future.
科研通智能强力驱动
Strongly Powered by AbleSci AI